|
Q1 FY2027
As of Jul 31, 2026
|
Q4 FY2026
As of Apr 30, 2026
|
Q3 FY2026
As of Jan 31, 2026
|
Q2 FY2026
As of Oct 31, 2025
|
Q1 FY2026
As of Jul 31, 2025
|
Q4 FY2025
As of Apr 30, 2025
|
Q3 FY2025
As of Jan 31, 2025
|
Q2 FY2025
As of Oct 31, 2024
|
Q1 FY2025
As of Jul 31, 2024
|
Q4 FY2024
As of Apr 30, 2024
|
Q3 FY2024
As of Jan 31, 2024
|
Q2 FY2024
As of Oct 31, 2023
|
Q1 FY2024
As of Jul 31, 2023
|
Q4 FY2023
As of Apr 30, 2023
|
Q3 FY2023
As of Jan 31, 2023
|
Q2 FY2023
As of Oct 31, 2022
|
Q1 FY2023
As of Jul 31, 2022
|
Q4 FY2022
As of Apr 30, 2022
|
Q3 FY2022
As of Jan 31, 2022
|
Q2 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Other current liability | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current operating lease liabilities | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Common stock, $.001 par value; 200,000,000 shares authorized; 14,038,902 and 14,007,159 shares issued; and 13,918,569 and 13,886,826 outstanding as of July 31, 2026 and April 30, 2026, respectively | ||||||||||||||||||||
| Treasury stock, at cost | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity attributable to Champions Oncology, Inc. | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
